Compare HP Inc (HPQ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Johnson & Johnson — how do they compare? HP Inc trades at $29.98 (market cap $29.25B), while Johnson & Johnson trades at $260.72 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 21.1× HP Inc's market cap, and HP Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Johnson & Johnson for 129 Days on average.
| HPQ | JNJ | |
|---|---|---|
Market Cap | $29.25B | $618.09B |
Volume | 10,025,806 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $35.48 | $278.43 |
52-Week Low | $18.20 | $186.00 |
Typical Hold Time | 69 Days | 129 Days |
Enterprise Value | $35.42B | $646.37B |
Dividend Yield | 3.7% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ is trading at $30.37, down 5.8% over the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $55.30 billion in 2025 and has beaten earnings estimates for the last three quarters. Recent news highlights HP's new product launches and a dividend payment scheduled for October 2026, though the stock faces pressure from a forecasted decline in PC sales for 2027.
The outlook for HPQ is mixed, with strong cash flow and consistent earnings beats providing support, but risks from a weakening PC market and high liabilities tempering upside. Analyst consensus is a hold with a price target of $25.75, suggesting cautious optimism amid industry headwinds. Investment opportunity lies in valuation metrics like a low P/E of 12.38, but execution risks remain key.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
